Search Results - "Van Ness, B"

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review by Fonseca, R, Bergsagel, P L, Drach, J, Shaughnessy, J, Gutierrez, N, Stewart, A K, Morgan, G, Van Ness, B, Chesi, M, Minvielle, S, Neri, A, Barlogie, B, Kuehl, W M, Liebisch, P, Davies, F, Chen-Kiang, S, Durie, B G M, Carrasco, R, Sezer, Orhan, Reiman, Tony, Pilarski, Linda, Avet-Loiseau, H

“…Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several subtypes of the disease have been identified at the…”
Get full text

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors by Mitra, A K, Mukherjee, U K, Harding, T, Jang, J S, Stessman, H, Li, Y, Abyzov, A, Jen, J, Kumar, S, Rajkumar, V, Van Ness, B

“…Multiple myeloma (MM) is characterized by significant genetic diversity at subclonal levels that have a defining role in the heterogeneity of tumor…”
Get full text

Clinical and biological significance of RAS mutations in multiple myeloma by Chng, W J, Gonzalez-Paz, N, Price-Troska, T, Jacobus, S, Rajkumar, S V, Oken, M M, Kyle, R A, Henderson, K J, Van Wier, S, Greipp, P, Van Ness, B, Fonseca, R

Get full text

Clinical significance of TP53 mutation in myeloma by Chng, W J, Price-Troska, T, Gonzalez-Paz, N, Van Wier, S, Jacobus, S, Blood, E, Henderson, K, Oken, M, Van Ness, B, Greipp, P, Rajkumar, S V, Fonseca, R

Get full text

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib by Stessman, H A F, Mansoor, A, Zhan, F, Janz, S, Linden, M A, Baughn, L B, Van Ness, B

Get full text

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma by Mitra, A K, Harding, T, Mukherjee, U K, Jang, J S, Li, Y, HongZheng, R, Jen, J, Sonneveld, P, Kumar, S, Kuehl, W M, Rajkumar, V, Van Ness, B

“…Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efficacy in the treatment of cancers,…”
Get full text

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma by Stessman, H A F, Lulla, A, Xia, T, Mitra, A, Harding, T, Mansoor, A, Myers, C L, Van Ness, B G, Dolloff, N G

Get full text

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy by FONSECA, R, OKEN, M. M, HARRINGTON, D, BAILEY, R. J, VAN WIER, S. A, HENDERSON, K. J, KAY, N. E, VAN NESS, B, GREIPP, P. R, DEWALD, G. W

“…Deletions of the long arm of chromosome 13 (13q-) are observed in patients with multiple myeloma (MM), are rarely observed in the monoclonal gammopathy of…”
Get full text

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells by CHEUNG, W-C, VAN NESS, B

“…In B cell development, interleukin-6 (IL-6) induces terminal maturation of B lymphocytes into antibody producing plasma cells. Terminal differentiated B cells…”
Get full text

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma by Durie, B G M, Van Ness, B, Ramos, C, Stephens, O, Haznadar, M, Hoering, A, Haessler, J, Katz, M S, Mundy, G R, Kyle, R A, Morgan, G J, Crowley, J, Barlogie, B, Shaughnessy, J

“…Bone disease in myeloma occurs as a result of complex interactions between myeloma cells and the bone marrow microenvironment. A custom-built DNA single…”
Get full text

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro by CHEUNG, W-C, VAN NESS, B

“…The bone marrow microenvironment supports growth and differentiation of normal hematopoietic cells and can contribute to malignant growth. Since myeloma cells…”
Get full text

Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis by LIU, P, OKEN, M, VAN NESS, B

“…Because of the increasing use of IFN-alpha in both induction and maintenance therapy for multiple myeloma (MM), its effect on growth and apoptosis of myeloma…”
Get full text

The structure of ownership and corporate acquisition strategies by Wright, Peter, Kroll, Mark, Lado, Augustine, Van Ness, Bonnie

“…In this study, we examine in an agency-theoretic context the influence of executive equity stakes upon corporate strategy and firm value. We argue that…”
Get full text

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement by BILLADEAU, D, PROSPER, F, VERFAILLIE, C, WEISDORF, D, VAN NESS, B

“…Treatment with combination chemotherapy has not resulted in long-term remissions in multiple myeloma (MM) despite advances in drug discovery and protocol…”
Get full text

Is Flow Cytometric DNA Content Hypodiploidy Prognostic in Multiple Myeloma? by Greipp, P. R., Trendle, M. C., Leong, T., Oken, M. M., Kay, N. E., Ness, B. Van, Kyle, R. A.

“…Hypodiploid multiple myeloma is uncommon when assessed by DNA content flow cytome-try, having been reported in less than 6% of patients with newly diagnosed…”
Get full text

Glucose-dependent regulation of glucose transport activity, protein, and mRNA in primary cultures of rat brain glial cells by Walker, P S, Donovan, J A, Van Ness, B G, Fellows, R E, Pessin, J E

“…D-Glucose deprivation of primary rat brain glial cell cultures, by incubation with 25 mM D-fructose for 24 h, resulted in a 4-5-fold induction of D-glucose…”
Get full text

Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486 by Trendle, M.C., Leong, T., Kyle, R.A., Katzmann, J.A., Oken, M.M., Kay, N.E., Van Ness, B.G., Greipp, P.R.

“…The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well‐established independent prognostic factor for patients with…”
Get full text

Initiation and processing of two kappa immunoglobulin germ line transcripts in mouse B cells by MARTIN, D. J, VAN NESS, B. G

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan by Rowley, Matt, Liu, Pocheng, Van Ness, Brian

“…Because there is no known genetic abnormality common to all patients with myeloma, it is important to understand how genetic heterogeneity may lead to…”
Get full text

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations : Analysis of the Eastern cooperative oncology group phase III trial by LIU, P, LEONG, T, QUAM, L, BILLADEAU, D, KAY, N. E, GREIPP, P, KYLE, R. A, OKEN, M. M, VAN NESS, B

“…Mutations of members of the ras family are among the most common oncogene mutations found in multiple myeloma (MM). We have examined the mutational status of…”
Get full text